BR112013023575A2 - “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes” - Google Patents

“derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”

Info

Publication number
BR112013023575A2
BR112013023575A2 BR112013023575A BR112013023575A BR112013023575A2 BR 112013023575 A2 BR112013023575 A2 BR 112013023575A2 BR 112013023575 A BR112013023575 A BR 112013023575A BR 112013023575 A BR112013023575 A BR 112013023575A BR 112013023575 A2 BR112013023575 A2 BR 112013023575A2
Authority
BR
Brazil
Prior art keywords
derivative
pharmaceutical composition
octahydrothienoquinoline
octahydrothienoquinoline derivative
pharmaceutical
Prior art date
Application number
BR112013023575A
Other languages
English (en)
Other versions
BR112013023575A8 (pt
BR112013023575B1 (pt
Inventor
Kiyoshi Kasai
Masaki Yoshida
Nirotaka Teranishi
Toshihiro Nishimura
Yasunori Ueno
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR112013023575A2 publication Critical patent/BR112013023575A2/pt
Publication of BR112013023575A8 publication Critical patent/BR112013023575A8/pt
Publication of BR112013023575B1 publication Critical patent/BR112013023575B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013023575-6A 2011-03-14 2012-03-12 Compostos derivados de octaidrotienoquinolina, composição farmacêutica e agente farmacêutico compreendendo os ditos compostos BR112013023575B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-055154 2011-03-14
JP2011055154 2011-03-14
PCT/JP2012/056252 WO2012124649A1 (ja) 2011-03-14 2012-03-12 新規なオクタヒドロチエノキノリン誘導体、それを含有する医薬組成物およびそれらの用途

Publications (3)

Publication Number Publication Date
BR112013023575A2 true BR112013023575A2 (pt) 2016-12-06
BR112013023575A8 BR112013023575A8 (pt) 2018-01-16
BR112013023575B1 BR112013023575B1 (pt) 2021-12-21

Family

ID=46830720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023575-6A BR112013023575B1 (pt) 2011-03-14 2012-03-12 Compostos derivados de octaidrotienoquinolina, composição farmacêutica e agente farmacêutico compreendendo os ditos compostos

Country Status (22)

Country Link
US (1) US9138434B2 (pt)
EP (1) EP2687532B1 (pt)
JP (1) JP5563716B2 (pt)
KR (1) KR101618624B1 (pt)
CN (2) CN104829628B (pt)
AU (1) AU2012227428B2 (pt)
BR (1) BR112013023575B1 (pt)
CA (1) CA2827629C (pt)
DK (1) DK2687532T3 (pt)
ES (1) ES2613658T3 (pt)
HK (1) HK1188791A1 (pt)
HU (1) HUE033449T2 (pt)
IL (1) IL228318A (pt)
MX (1) MX343077B (pt)
MY (1) MY183288A (pt)
PL (1) PL2687532T3 (pt)
PT (1) PT2687532T (pt)
RU (1) RU2573399C2 (pt)
SG (1) SG193400A1 (pt)
TW (1) TWI537274B (pt)
WO (1) WO2012124649A1 (pt)
ZA (1) ZA201306905B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6166990B2 (ja) * 2012-09-12 2017-07-19 キッセイ薬品工業株式会社 オクタヒドロチエノキノリン誘導体の製造方法及びその製造中間体
US9585885B2 (en) 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
WO2014112492A1 (ja) * 2013-01-17 2014-07-24 キッセイ薬品工業株式会社 新規なオクタヒドロキノリン誘導体、それを含有する医薬組成物およびそれらの用途
KR102169337B1 (ko) 2018-08-22 2020-10-23 주식회사 도원엔바이로 질소와 인의 흡착형 세라믹 미생물 담체 및 이의 제조방법
EP4177257A1 (en) * 2020-07-06 2023-05-10 Kissei Pharmaceutical Co., Ltd. Succinate of octahydrothienoquinoline compound, and crystals thereof
JPWO2022075347A1 (pt) * 2020-10-07 2022-04-14

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
BG17786A3 (pt) 1970-08-14 1973-12-25
US4166182A (en) 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
DK268979A (da) 1979-01-22 1980-07-23 Lilly Co Eli Fremgangsmaade til fremstilling af octahydro-2h-pyrrolo (3,4-g)quinoliner
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US4452808A (en) 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4501890A (en) * 1983-09-26 1985-02-26 Eli Lilly And Company Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4537893A (en) 1984-04-27 1985-08-27 Eli Lilly And Company Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4826986A (en) 1986-06-16 1989-05-02 Eli Lilly And Company 6-Oxo-trans-octa- and decahydroquinolines
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池

Also Published As

Publication number Publication date
CA2827629A1 (en) 2012-09-20
BR112013023575A8 (pt) 2018-01-16
NZ615293A (en) 2014-08-29
DK2687532T3 (en) 2017-02-20
AU2012227428B2 (en) 2016-05-05
KR20140010137A (ko) 2014-01-23
BR112013023575B1 (pt) 2021-12-21
CN103443106B (zh) 2015-09-30
US20140243311A1 (en) 2014-08-28
HK1188791A1 (zh) 2014-05-16
IL228318A0 (en) 2013-11-25
HUE033449T2 (en) 2017-11-28
TW201242970A (en) 2012-11-01
US9138434B2 (en) 2015-09-22
IL228318A (en) 2017-07-31
EP2687532B1 (en) 2016-12-14
SG193400A1 (en) 2013-10-30
MX2013010587A (es) 2013-10-07
MX343077B (es) 2016-10-24
EP2687532A4 (en) 2014-08-13
CA2827629C (en) 2019-01-08
ZA201306905B (en) 2014-12-23
WO2012124649A1 (ja) 2012-09-20
CN104829628B (zh) 2018-01-09
PL2687532T3 (pl) 2017-06-30
ES2613658T3 (es) 2017-05-25
RU2013145799A (ru) 2015-04-20
AU2012227428A1 (en) 2013-09-26
JPWO2012124649A1 (ja) 2014-07-24
KR101618624B1 (ko) 2016-05-09
CN103443106A (zh) 2013-12-11
PT2687532T (pt) 2017-03-22
RU2573399C2 (ru) 2016-01-20
CN104829628A (zh) 2015-08-12
EP2687532A1 (en) 2014-01-22
JP5563716B2 (ja) 2014-07-30
MY183288A (en) 2021-02-18
TWI537274B (zh) 2016-06-11

Similar Documents

Publication Publication Date Title
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112013023681A2 (pt) compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
BR112015002738A2 (pt) composto , e , composição farmacêutica
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2012, OBSERVADAS AS CONDICOES LEGAIS.